Hormone Replacement Therapy and Vascular Risk Disorders in Adult Hypopituitarism

Kaji, Hidesuke; Iida, Keiji; Takahashi, Yutaka; Okimura, Yasuhiko; Chihara, Kazauo

doi:10.1507/endocrj.k06-129

Cited by 12 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown a high prevalence of cardiovascular risk factors (hyperglycaemia, hypertension, dyslipidaemia and changes in body composition) in patients diagnosed with hypopituitarism. In the present study, the prevalence of each cardiovascular risk factor was lower than previously reported, probably related to a lower incidence of obesity …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients

Fernández-Rodríguez

López-Ratón

Andujar

et al. 2013

Clinical Endocrinology

View full text Add to dashboard Cite

Prevalence of hypopituitarism was 37·5 cases/100 000 inhabitants, and annual incidence was 2·07 cases/100 000 inhabitants. SMR was 8 times higher in hypopituitarism than in general population and was also higher in males and younger patients. Reduced survival was significantly related to cancer, nontumoural causes of hypopituitarism, older age at diagnosis, previous radiotherapy and diabetes mellitus with poor metabolic control.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The initial clinical expression of hypopituitarism is often mild and nonspecific, which can lead to a delayed diagnosis . Compared to the general population, patients with hypopituitarism have increased morbidity and mortality, especially because of cardiovascular disease …”

Section: Introductionmentioning

confidence: 99%

Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients

Fernández-Rodríguez

López-Ratón

Andujar

et al. 2013

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Furthermore, most patients in this study had multiple pituitary hormone deficiencies and the majority of women with gonadotropin deficiency were receiving oral estrogen replacement. As several reports indicate hormone replacement therapy itself plays some role in the development of metabolic disorders including dyslipidemia [14,15], the possibility cannot be ruled out that hormone replacement therapy contributes to the development of dyslipidemia.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Co-Morbidities Revealed in Patients with Childhood-Onset Adult GH Deficiency after Cessation of GH Replacement Therapy for Short Stature

et al. 2008

View full text Add to dashboard Cite

Abstract. GH therapy was approved in 2006 for treatment of adult growth hormone deficiency (GHD) in Japan. Until then, GH was used only to treat short stature in children with GHD and the treatment was stopped when the final height was reached. In the present study, we investigated metabolic co-morbidities experienced by adults with childhood-onset (CO) GHD after the cessation of GH. Forty-two patients with COGHD (M/F 22/20, age at follow up when the retrospective analysis was carried out: 18-52 yr) treated with GH in childhood were studied. We reviewed the medical records of these patients to determine the metabolic co-morbidities that developed after cessation of GH. The median age was 19 yrs (range: 14-38) at cessation of GH, and the following co-morbidities were observed: hypertriglyceridemia in 15 (41%) patients, non-alcoholic fatty liver disease (NAFLD) in 11 (29%) patients, hypercholesterolemia in 10 (26%) patients, diabetes mellitus (DM) in 4 (10%) patients, and hypertension in 1 (2.4%) patient. The median BMI when these complications became overt was 23.5 kg/m 2 for those with hypertriglyceridemia, 26.0 kg/m 2 for those with NAFLD, 20.9 kg/m 2 for those with hypercholesterolemia, and 27.2 kg/m 2 for those with DM. More than two co-morbidities were experienced by 32% of men and 30% of women. In conclusion, adults with COGHD after the cessation of GH have multiple metabolic co-morbidities. Lifelong GH replacement might be important for improving the overall metabolic profiles in these patients.

show abstract

“…18 In humans, a higher prevalence of obesity was suggested in patients with AVP deficiency or in subjects with reduced AVP activity. 19,20 Recently, Enhorning et al 21 studied polymorphism rs1042615 of the V1a receptor in middle-aged humans in southern Sweden (nϭ5506; CC, CT, and TTϭ30.4%, 49.2%, 20.4%) and reported that CTϩTT subjects had significantly higher blood glucose concentration and a tendency toward a higher prevalence of obesity than CC subjects. Similarly, in this study, TT men had slightly higher blood glucose concentration, although not significant, and significantly higher BMI (Figure 1), and, moreover, overweight men in Figure 3 show significantly higher T allele frequency.…”

Section: Bmi and Blood Pressure Before Training And V1a Receptor Polymentioning

confidence: 99%

Vasopressin V1a Receptor Polymorphism and Interval Walking Training Effects in Middle-Aged and Older People

et al. 2010

View full text Add to dashboard Cite

Abstract-We assessed whether single nucleotide polymorphism rs1042615 of the vasopressin V1a receptor altered the indices of lifestyle-related diseases in middle-aged and older people (meanϮSD: 64Ϯ7 years), and, if so, whether it also altered the effects of interval walking training (IWT). CC, CT, and TT carriers of rs1042615 (42, 118, and 64 men, respectively; 113, 263, and 154 women, respectively) performed IWT. We included 5 sets of 3-minute fast walking at Ն70% peak aerobic capacity for walking and 3-minute slow walking at 40% peak aerobic capacity per day for Ն4 days per week for 5 months. Before IWT, the body mass index and diastolic blood pressure (DBP) for men were 25.1Ϯ0.3 kg/m 2 (meanϮSE) and 84Ϯ1 mm Hg in TT, higher than the 23.6Ϯ0.4 kg/m 2 and 78Ϯ1 mm Hg in CC, respectively (PϽ0.01), differences that disappeared after IWT despite similar training achievement between groups (PϾ0.6). After IWT, body mass index and DBP decreased in TT (Ϫ0.9Ϯ0.1 kg/m 2 and Ϫ5Ϯ1 mm Hg, respectively), more than in CC (Ϫ0.5Ϯ0.1 kg/m 2 and 1Ϯ1 mm Hg, respectively; PϽ0.05), with a greater decrease in low-density lipoprotein cholesterol in TT than CC carriers (PϽ0.01). The decreases in DBP and low-density lipoprotein cholesterol were still greater in TT carriers even after adjustment for their pretraining values. On the other hand, for women, these parameters before IWT and their changes after IWT were similar among CC, CT, and TT carriers. Thus, polymorphism rs1042615 of the V1a receptor altered body mass index and DBP in middle-aged and older men and the training-induced responses of DBP and low-density lipoprotein cholesterol, whereas women did not show any of these responses. Key Words: exercise training Ⅲ elderly Ⅲ hypertension Ⅲ obesity Ⅲ cholesterol Ⅲ receptors Ⅲ vasopressin Ⅲ polymorphism A ccumulated evidence suggests the importance of obesity prevention to protect against age-and lifestyle-related diseases, such as hypertension. [1][2][3][4] Although exercise training has been highlighted as one of the most effective strategies, 4 -7 few studies have assessed how gene polymorphisms affect interindividual variation in response to exercise training in a large population of middle-aged and older people. 8 This might be because there have been no uniformly and broadly available exercise training regimens calibrated to their individual physical fitness with few limitations on time and place. Without such a regimen, it might have been difficult to distinguish which caused the interindividual variation in the effects of exercise training, genetic or training regimen differences.Recently, we have developed an exercise training regimen fitted to individual physical fitness broadly available in middle-aged and older people by combining interval walking training (IWT) and an information technology network system to track exercise intensity in individuals. 9,10 Because the IWT regimen is so simple and because training achievements can be measured precisely by triaxial accelerometry, 11 they have enabled us to seek polymorphisms...

show abstract

Hormone Replacement Therapy and Vascular Risk Disorders in Adult Hypopituitarism

Cited by 12 publications

References 25 publications

Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients

Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients

Metabolic Co-Morbidities Revealed in Patients with Childhood-Onset Adult GH Deficiency after Cessation of GH Replacement Therapy for Short Stature

Vasopressin V1a Receptor Polymorphism and Interval Walking Training Effects in Middle-Aged and Older People

Contact Info

Product

Resources

About